1, 4, 6-Androstatriene-3, 17-Dione (ATD)
|Purchase Qty. (G)||FOB Price|
|10-99||US $9 / G|
|100-999||US $2.3 / G|
|1,000+||US $1.4 / G|
ATD is present in some over-the-counter bodybuilding supplements as well as Topical ATD solutions that work transdermally.
While not banned, ATD may cause positive urinalysis results. ATD may cause a positive test for the anabolic steroid boldenone, of which it is a metabolite and is also prohibited in amateur and professional sports which forbids aromatase inhibitors.
Androsta-1,4,6-triene-3,17-dione (ATD) is an irreversible steroidal aromatase inhibitor and is marketed as a supplement. It has been reported to effectively reduce estrogen biosynthesis and significantly increase the levels of endogenous steroids such as dihydrotestosterone and testosterone in human. ATD abuses have been reported in human sports. Its metabolism in human has been studied, and the in vitro metabolic study of ATD in horses has been reported, however, little is known about its biotransformation and elimination in horses. This paper describes the in vitro and in vivo metabolism studies of ATD in horses, with an objective of identifying the target metabolites with the longest detection time for controlling ATD abuse. In vitro metabolism studies of ATD were performed using homogenized horse liver. ATD was found to be extensively metabolized, and its metabolites could not be easily characterized by gas chromatography/mass spectrometry (GC/MS) due to insufficient sensitivity.